Tetraphase Pharmaceuticals has announced the commercial launch of Xerava (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in patients ≥18 years old. As Xerava is a fully-synthetic fluorocycline antibacterial that is structurally similar to tetracyclines, treatment is contraindicated in patients with known hypersensitivity to tetracycline-class antibacterial drugs.
Duration of therapy with Xerava for cIAI can range from 4 to 14 days; treatment duration should be guided by the severity and location of infection and the patient’s clinical response. Dosage adjustment is recommended for patients with severe hepatic impairment (Child Pugh C) and in patients taking concomitant strong CYP3A inducers.
Each single-dose vial of Xerava contains 50mg of eravacycline (equivalent to 63.5mg eravacycline dihydrochloride) as a lyophilized powder for reconstitution and further dilution.
“With a WAC price of $175 per treatment day, Xerava is well-suited for empiric use and is now available to hospitals to treat a range of appropriate patients with empiric and confirmed infections,” said Larry Edwards, Chief Operating Officer of Tetraphase.
For more information visit Xerava.com.